March 27, 2017 / 8:26 PM / 4 months ago

BRIEF-Tesaro to expand development program for Niraparib drug

1 Min Read

March 27 (Reuters) - Tesaro Inc

* Tesaro announces expanded development program for Niraparib focused on the treatment of front-line metastatic ovarian and lung cancers and metastatic breast cancer

* Tesaro - also expect to initiate new trial of Niraparib in combination with anti-pd-1 antibody in women with metastatic triple-negative breast cancer Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below